Status:
COMPLETED
A Clinical Evaluation of the Next Generation Diagnostic Instrument (NGDI)
Lead Sponsor:
Bausch & Lomb Incorporated
Conditions:
Healthy
Eligibility:
All Genders
21-75 years
Phase:
NA
Brief Summary
The purpose of this study is to measure the aberrations, corneal surface topography and pachymetry of normal human eyes with the NGDI.
Eligibility Criteria
Inclusion
- +10.00D to -20.00D of absolute spherical ametropia
- Must be part of the Bausch \& Lomb research clinic
- Snellen visual acuity must be correctable to 20/25
Exclusion
- No more than -6.00D of refractive astigmatism
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2006
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT00347594
Start Date
August 1 2005
End Date
September 1 2006
Last Update
January 17 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bausch & Lomb
Rochester, New York, United States, 14609